Your browser doesn't support javascript.
loading
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Sentís, Alexis; Kislaya, Irina; Nicolay, Nathalie; Meijerink, Hinta; Starrfelt, Jostein; Martínez-Baz, Iván; Castilla, Jesús; Nielsen, Katrine Finderup; Hansen, Christian Holm; Emborg, Hanne-Dorthe; Nardone, Anthony; Derrough, Tarik; Valenciano, Marta; Nunes, Baltazar; Monge, Susana.
Afiliación
  • Sentís A; Epidemiology Department, Epiconcept, Paris, France.
  • Kislaya I; Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisbon, Portugal.
  • Nicolay N; Vaccine preventable diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
  • Meijerink H; Norwegian Institute of Public Health (NIPH), Oslo, Norway.
  • Starrfelt J; Norwegian Institute of Public Health (NIPH), Oslo, Norway.
  • Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
  • Castilla J; CIBER on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Nielsen KF; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
  • Hansen CH; CIBER on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Emborg HD; Statens Serum Institut (SSI), Copenhagen, Denmark.
  • Nardone A; Statens Serum Institut (SSI), Copenhagen, Denmark.
  • Derrough T; Statens Serum Institut (SSI), Copenhagen, Denmark.
  • Valenciano M; Epidemiology Department, Epiconcept, Paris, France.
  • Nunes B; Vaccine preventable diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
  • Monge S; Epidemiology Department, Epiconcept, Paris, France.
Euro Surveill ; 27(30)2022 07.
Article en En | MEDLINE | ID: mdl-35904059
ABSTRACT
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Aged / Humans Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Aged / Humans Idioma: En Revista: Euro Surveill Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Francia